Items tagged with Vaccines
Exciting new vaccine targets killer disease TB (post)
Australian medical researchers from the Centenary Institute and the University of Sydney have successfully developed and tested a new type of vaccine targeting tuberculosis (TB), the world's top infectious disease killer.
Results from new trial of the candidate TB vaccine MTBVAC offer hope for control of TB in infants (post)
First trial of a new live attenuated Mycobacterium tuberculosis vaccine in infants.
Lancet Series: Tuberculosis 2019 (post)
Executive summary
NIH awards contracts to advance tuberculosis immunology research (post)
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded $30 million in first-year funding to establish new centers for immunology research to accelerate progress in tuberculosis (TB) vaccine development.
BCG vaccination associated with lower prevalence of LTBI in adults (post)
Bacille Calmette-Guérin, or BCG, vaccination is associated with a lower prevalence of latent tuberculosis infection in adult TB contacts and could protect against Mycobacterium tuberculosis infection, according to results published in Journal of Infectious Diseases.
BCG vax: A shot against lung cancer in native populations? (post)
American Indian/Alaskan Native adults who received the bacillus Calmette-Guerin (BCG) vaccine against tuberculosis (TB) as children had lower rates of lung cancer, a secondary analysis of a randomized trial found.
GSK candidate vaccine demonstrates sustained level of protection against active pulmonary TB (post)
-- Final analysis of phase IIb study published today in the New England Journal of Medicine and presented at the 50th Union World Conference on Lung Health.
-- Final results confirm the innovative TB candidate vaccine’s efficacy level and acceptable safety profile in three-year clinical trial conducted in sub-Saharan African regions.
50th Union World Conference on Lung Health: NIH announces $30 million for research to spur TB vaccine development (post)
HYDERABAD, INDIA – The National Institute of Allergy and Infectious Diseases will dedicate $30 million in new funding to accelerate development of new vaccines against tuberculosis.
Changed route of immunization dramatically improves efficacy of TB vaccine (post)
Tuberculosis (TB), an ancient disease, is the leading infectious cause of death globally, yet the world’s only licensed TB vaccine, Bacille Calmette-Guerin (BCG), was developed a century ago. Given to infants via a needle placed just under the skin, BCG protects babies from a form of the disease called disseminated TB but is far less effective at preventing pulmonary TB, the major cause of illness and deaths, in teens or adults.
BCG revaccination shows potential to boost immunity against TB (post)
When young Indian adults, who have been vaccinated at birth, are once again given the BCG vaccine, their immune response against tuberculosis (TB) improves and they may be less likely to develop the disease, finds a new study led by scientists at the Centre for Infectious Diseases Research (CIDR), Indian Institute of Science (IISc).
Page 13 of 30 · Total posts: 0
←First 12 13 14 Last→